Studies examining an impact of IOL in SCT for hematologic malignancies

Table. Studies examining an impact of IOL in SCT for hematologic malignancies, and including a multivariate analysis or ROC analysis. For retrospective analyses, studies of ≥50 patients were included; for prospective analyses, ≥25 patients.
Analysis	SCT	N	Diseases	IOL	Infection	Relapse	NRM	TRM	OS	Other	Comments	Reference
Retro	MA	543	Multiple	Pre SF				0.002 (for MDS)	<0.00125	SOS 0.05, aGVH NS	Included albumin	Armand 2007
Retro	Allo NOS	172	MDS, AML	Pre SF	0.032 BSI				NS			Platzbecker 2008
Retro	MA & RIC	217	MDS	Pre SF TD pre		NS	0.03 0.023		0.01 0.003		Still sig adj for albumin NS in RIC	Alessandrino 2010
Retro	Allo NOS	101	Multiple	Pre SF	NS	NS		0.003	0.001	SOS NS		Lee 2009
Retro	MA & NMA	264	Multiple	Pre SF	Infectious deaths 0.01		0.01@5y	0.05@5y		Organ failure deaths 0.02		Kataoka 2009
Retro	Allo NOS	1448	Multiple	Pre SF				0.03@2y	≤0.005		NRM NS for NMA	Sorror 2009
Retro	MA	222	Multiple	Pre SF		0.003 RFS			0.003			Mahindra 2009
Retro	MA & RIC	477	Multiple	Pre SF	NS							Dadwal 2015
Retro	Allo NOS	84	Multiple	Pre SF	<0.023	0.039 DFS			0.023	Engraftment, aGVH NS		Sivgin 2012
Retro	MA	230	Multiple	Pre SF					<0.001		ROC analysis	Bazuaye 2012
Retro	MA & RIC	114	AML, MDS	Pre SF	D100 BSI 0.02						Time to engraftment 0.03	Tachibana 2011
Retro	Allo NOS	261	AL, MDS	Pre SF		≤0.031 DFS			≤0.043			Tachibana 2012
Retro	MA & RIC	158	Multiple	Pre SF				0.04	0.002			Michallet 2013
Retro	Allo NOS	290	Multiple	Pre SF				Increased (P NR)	<0.02		OS sig @ 0-6, 6-12, 12-24 & 25-60 mo	Meyer 2013
Retro	MA & RIC	309	Multiple	Pre SF		0.015, 0.002 RFS		0.023	0.013			Wahlin 2011
Retro	MA, RIC, NMA	3917	Multiple	Pre SF			0.002 for SF >2500		0.02, 0.001 for SF >1000, >2500			Vaughn 2015
Retro	MA	59	Multiple	LIC at necropsy	Invasive aspergillus 0.012							Altes 2004
Retro	MA¹	1248	Multiple	Pre(?) SF	Invasive mold <40d 0.02							Garcia-Vidal 2008
Retro	RIC	99	MDS, AML²	Pre SF		NS, DFS NS		NS	0.03			Lim 2010
Retro	NMA	64	Multiple	Pre SF		NS	NS		0.01	aGVH NS		Mahindra 2009
Retro	Allo NOS & ASCT	55	Multiple	Pre hepcidin	Bacterial 0.007							Kanda 2008
Retro	MA & ASCT	148	Multiple	Pre SF	Pulm fungal 0.045							Ozyilmaz 2010
Retro	MA, NMA & ASCT	427		Pre SF						SOS 0.04		Maradei 2009
Retro	MA, NMA & ASCT	77	Multiple	BMIS	0.02 IRM			0.03	0.01		SF, RBC TR, BM iron stores	Storey 2009
Retro	ASCT	315	HL & NHL	Pre SF		0.049, 0.021 RFS			0.002			Mahindra 2008
Retro	ASCT	367	MM	BMIS	Severe <0.001							Miceli 2006

Meta-analysis	MA & RIC	276	Multiple	SF pre			0.026 RIC		0.036		Including CRP	Armand 2014

Pro	MA	45	MDS, AL	SF, LIC by MRI		SF, LIC NS	SF, LIC NS		SF p=0.042 LIC NS	LIC NS	Including CRP	Armand 2012³
Pro	MA & RIC	190	Multiple	SF pre	0.032 BSI			0.004	0.013@100d	0.001 severe GVH		Pullarkat 2008
Pro	MA & RIC	190	AML, AL	Pre SF	NS@100d	NS	NS	EFS NS	0.017	Grade II-IV aGVH NS		Tanaka 2015
Pro	MA & RIC	67	Multiple	LIC by MRI	0.003 severe			LIC NS	LIC NS			Virtanen 2013³
Pro	Allo NOS	133	AML, MDS	LIC by MRI, LPI	0.023 bacteremia LPI		D100 0.002 LPI					Wermke 2015
Pro	MA & RIC	88	MDS, AML	Pre SF, LIC by MRI, LPI			0.016 LIC		0.038 LIC			Wermke 2012³
Pro	MA & RIC	102	Multiple	Post SF, LIC by SQUID	0.006 IFI							Busca 2010
Pro	MA & RIC	88	Multiple	Pre SF, LIC by MRI			SF 0.03 LIC NS		SF 0.05			Trottier 2013³
Pro	Allo NOS & ASCT	25	Multiple	Pre SF, TS				0.01	LIC NS ≤0.02	Grade III-IV aGVH <0.01		Altes 2002
Pro	MA, RIC & ASCT	50	Multiple	Pre SF, TS >80%	0.006, 0.012 invasive aspergillus					Severe mucositis SF 0.03		Altes 2007
¹predominantly ²secondary ³included in meta-analysis. adj, adjusted; aGVH, acute GVH; AL, acute leukemia; Allo, allogeneic; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; BM, bone marrow; BMIS, bone marrow iron score; BSI, bloodstream infection; CRP, C-reactive protein; D, day; DFS, disease-free survival; EFS, event-free survival; GVH, graft versus host; HL, Hodgkin lymphoma; IFI, invasive fungal infection; IOL, iron overload; IRM, infection related mortality; LIC, liver iron concentration; LPI, labile plasma iron; MA, myeloablative; MM, multiple myeloma; mo, months; MRI, magnetic resonance imaging; NHL, non-Hodgkin lymphoma; NMA, non-myeloablative; n, number; NOS, not otherwise specified; NR, not reported; NRM, non-relapse mortality; NS, not significant; OS, overall survival; p, probability; pro, prospective; pulm, pulmonary; RBC, red blood cell; retro, retrospective; RFS, relapse free survival; RIC, reduced intensity conditioning; ROC, receiver-operator curve; SCT, stem cell transplantation, SF, serum ferritin; sig, significant; SOS, sinusoidal obstructive syndrome; SQUID, Superconducting Quantum Interference Device; TD, transfusion dependent; TR, transfusion requirement; TRM, transplant-related mortality; TS, transferrin saturation; y, years. From: Leitch HA, et al. Crit Rev Oncol Hematol. 2017;113:156-170.